Literature DB >> 20227035

The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3.

Gordon B Mills1, Yosef Yarden.   

Abstract

Several cancer drugs intercept the ErbB family receptors EGFR (ErbB-1) and HER2 (ErbB-2). However, the therapeutic value of targeting ErbB-3 has been less clear. A report in this issue of Cancer Cell by Sheng et al. renews hopes that intercepting ErbB-3-mediated autocrine loops bears potential for treatment of ovarian cancer. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 20227035     DOI： 10.1016/j.ccr.2010.02.023

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

Review 1.  Coordinated dysregulation of cancer progression by the HER family and p21-activated kinases.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Ravikumar Amjesh; Bijesh George; M Radhakrishna Pillai
Journal:  Cancer Metastasis Rev       Date:  2020-08-21       Impact factor: 9.264

2.  Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells.

Authors:  Hui Lyu; Jingcao Huang; Zhimin He; Bolin Liu
Journal:  Biol Proced Online       Date:  2018-08-08       Impact factor: 3.244

3.  Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.

Authors:  Hui Lyu; Shuiliang Wang; Jingcao Huang; Bolun Wang; Zhimin He; Bolin Liu
Journal:  Cancer Lett       Date:  2018-01-31       Impact factor: 8.679

Review 4.  Development of Effective Therapeutics Targeting HER3 for Cancer Treatment.

Authors:  Xiaolong Liu; Shuang Liu; Hui Lyu; Adam I Riker; Yamin Zhang; Bolin Liu
Journal:  Biol Proced Online       Date:  2019-03-19       Impact factor: 3.244

5.  Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.

Authors:  Adam J Camblin; Gege Tan; Michael D Curley; Isabel Yannatos; Sergio Iadevaia; Victoria Rimkunas; Mari Mino-Kenudson; Troy Bloom; Birgit Schoeberl; Daryl C Drummond; Alexey A Lugovskoy; Chrystal U Louis; Vasileios Askoxylakis
Journal:  Sci Rep       Date:  2019-11-14       Impact factor: 4.379

6.  The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.

Authors:  Jingcao Huang; Shuiliang Wang; Hui Lyu; Bo Cai; XiaoHe Yang; Jianxiang Wang; Bolin Liu
Journal:  Mol Cancer       Date:  2013-11-11       Impact factor: 27.401

Review 7.  Targeting of erbB3 receptor to overcome resistance in cancer treatment.

Authors:  Jian Ma; Hui Lyu; Jingcao Huang; Bolin Liu
Journal:  Mol Cancer       Date:  2014-05-08       Impact factor: 27.401

Review 8.  Understanding the biology of HER3 receptor as a therapeutic target in human cancer.

Authors:  Hui Lyu; Amy Han; Erik Polsdofer; Shuang Liu; Bolin Liu
Journal:  Acta Pharm Sin B       Date:  2018-06-02       Impact factor: 11.413
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.